Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 43.03
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of GRAL is 107 and suggests 148% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Data is available to registered users only
Buy
Sell